Navigation Links
ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
Date:7/1/2008

SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based biomodulator of 5-FU (5 fluorouracil), for the treatment of first-line metastatic colorectal cancer. The primary endpoint of the study was progression-free survival, which is expected to mature and be reported by the Company along with safety data later this year.

Data from the 85 patients treated in the study demonstrated a 39.0% objective response rate in the CoFactor/5-FU/Avastin(R) experimental arm compared to a 31.8% objective response rate in the leucovorin/5-FU/Avastin control arm. The data also demonstrated a 48.8% stable disease rate and 4.8% progressive disease rate in the CoFactor experimental arm compared to a 38.6% stable disease rate and 15.9% progressive disease rate in the leucovorin control arm. Objective response rate was measured according to RECIST criteria and was based on the number of complete responses and partial responses observed in this study based on investigators' assessments. In the study, both CoFactor and 5-FU were administered as an i.v. bolus. Currently, there are 10 patients receiving treatment in this study, with 6 patients on the CoFactor experimental arm and 4 patients on the leucovorin control arm.

Based on the data available at this time, the Company intends to evaluate potential options for the continued development of CoFactor. As the Company makes progress it anticipates providing updates regarding its development plans for CoFactor.

"As we evaluate further safety and efficacy data from our Phase 3 trial and the results of our pharmacokinetic bri
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
(Date:8/21/2014)... Germany , Aug. 21, 2014  IBM (NYSE: ... Elektronen-Synchrotron ( DESY ), a leading national research center ... management and storage of massive volumes of x-ray data. ... based on IBM software defined technology can handle more ... performance and help scientists worldwide gain faster insights into ...
(Date:8/21/2014)... 2014 BreedIT Corp., (OTCQB: ... exclusive worldwide license holder and distributor of highly ... researchers, today is pleased to announce the formation ... Ltd, a leading Israeli medical Cannabis breeder. ... new breeds of medical Cannabis to meet the ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... SAN DIEGO, June 16, 2011 Neurocrine Biosciences, Inc. ... elagolix presentations have been accepted for the scientific program ... September 4-7, 2011 in Montpellier, France. This important meeting ... every three years, bringing together clinicians and basic scientists ...
... 2011 Cebix Incorporated announced today it ... for the treatment of complications of diabetes. The biopharmaceutical ... evaluate Ersatta™, its proprietary long-acting form of C-peptide, in ... disease, lack this endogenous peptide.  Following the successful completion ...
Cached Medicine Technology:Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis 2Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 2Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 4
(Date:8/22/2014)... Home Care Assistance of Centennial , North ... proud to announce the next installment in its renowned ... Dr. Suzanne Steinbaum, attending cardiologist and Director of Women’s ... City, National Spokesperson for the American Heart Association’s Go ... issues surrounding women and heart disease, what heart disease ...
(Date:8/22/2014)... -- College can be a challenging time for young people, ... to make the most of their new life, an expert ... new people and learn to manage the temptations of new ... at St. John,s University in New York City, said in ... in the classroom. College is a time when students transition ...
(Date:8/22/2014)... ItsHot.com, a client-centric manufacturer, wholesaler and ... on its range of beautiful diamond heart pendants. Customers ... Hearts 14K White Rose Gold Diamond Heart Pendant, which ... 77%. Previously priced at $3,715.00, customers can now buy ... of this mesmerizing pendant embedded with 0.66 carats round ...
(Date:8/22/2014)... According to the new research report "Isocyanate Market ... Forecast to 2019" defines and segments the isocyanate ... market value. The isocyanate material market value will ... significant CAGR from 2014 to 2019. , Browse ... through 286 pages and in-depth TOC on "Isocyanate ...
(Date:8/22/2014)... approx. 265,000 Danes are acutely admitted to medical departments ... University and Aarhus University Hospital now shows that many ... are sent home again without receiving a diagnosis ... hospitalisation., "Naturally, there is no need for a diagnosis ... is a serious illness. So some patients will always ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:College Prep 101 2Health News:ItsHot.com Now Offers 60-80% Discount on its Striking Collection of Diamond Heart Pendants 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:Many patients are discharged without a diagnosis 2
... NHS hospital is, the higher the MRSA infection rate, research ... ,The impact of risk management standards on the frequency ... demanding risk management standards imposed by hospital insurers — and ... — could reduce MRSA infection rates. ,Institutions ...
... the US. Striking a blow for the pro-choice sections, New ... bill that would strengthen abortion rights. ,Only last ... Abortion Ban Act, signed by President Bush in 2003. The ... doctors say are often the safest and best to protect ...
... A team of researchers at the John Hopkins Hospital in the ... to the PSA to detect prostate cancer.// ,The new ... in a simple blood test. ,Prostate cancer, the ... areas of medicine. Physicians are unsure how to find it and ...
... little to maintaining one's health after all. A new UK study ... philosophically muse about flesh being heir to a thousand natural shocks, ... ,But the UK researchers point to a striking discrimination in the ... ages a person eight years earlier than high earners. ...
... food. That is a far more sensible way of fighting the ... , In fact prescription drugs to prevent diabetes cannot be ... ,Trials show rosiglitazone pills do work, but so does weight ... 2 diabetes, the researchers argue. ,In the British ...
... Research has shown a way for people suffering diabetic ... as alleviating the effects of diabetic retinopathy,// which is ... ,In the initial stages, retinopathy does not portray ... to cause the blood vessels of the eye to ...
Cached Medicine News:Health News:Better Risk Management Could Cut MRSA Infection Rates 2Health News:New York Governor to Introduce Bill to Strengthen Abortion Rights 2Health News:New blood test to detect prostate cancer 2Health News:Lower the wages, the faster one ages, UK study shows 2Health News:Lifestyle changes not prescription drugs to fight diabetes, say scientists 2
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: